alexa
Reach Us +1-218-451-2974

GET THE APP

Alternative Models For Drug Discovery In Alzheimer′s Disease | 57420
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google scholar citation report
Citations : 2275

Journal of Alzheimers Disease & Parkinsonism received 2275 citations as per google scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Alternative Models for Drug Discovery in Alzheimer′s Disease

5th International Conference on Alzheimer’s Disease & Dementia

Jordan L Holtzman

University of Minnesota, USA

Keynote: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460.C1.020

Abstract
Alzheimer’s disease is described as a progressive dementia associated with the extracellular deposits in the brain of a garbage protein, β-amyloid (Aβ), and the intracellular deposits of tangles. The vast majority of the patients develop the disease in old age while a small portion have an early onset, familial form. Since the 1970’s it has been generally assumed that the dementia seen in the two forms is due to the neurotoxicity of the Aβ. With the purification and sequencing of Aβ in the 1990’s investigators were able to identify the mutations associated with the familial forms. A number of laboratories transfected mice with these mutated genes. Since these animals exhibited many of the pathological and clinical manifestations of the late onset disease, they have been used to screen for new therapeutic agents. Unfortunately, all 244 drugs identified in these models have failed in clinical trials in elderly patients. Work from my laboratory has suggested that plaque deposits of Aβ rather than causing the dementia is merely a biomarker for a decline in the capacity of the endoplasmic reticulum (ER) in the cells to catalyze the posttranslational processing of 40% of cellular proteins, including those synaptic, membrane proteins required for a functioning memory. This paradigm is based on our observation that in the CSF all Aβ is normally N-glycosylated and bound to ER proteins, ERp57 and calreticulin. These data suggest a new direction for drug discovery in which agents are screened for their ability to increase the levels in cell lines of fluorescently labeled components of the ER post-translational pathway. The development of these cell lines would permit rapid screening for potential therapeutic agents in plate readers.
Biography

Jordan L. Holtzman, M.D., Ph.D. is Professor, Departments of Pharmacology and Medicine and Division of Environmental Health Sciences, University of Minnesota, Minneapolis, USA. He was graduated from University of Chicago, the Pritzker School of Medicine in 1959. He completed internship from University Ill Rsc/Ed in 1960.

Email: [email protected]

Top